COMMUNIQUÉS West-GlobeNewswire

Onconova Announces Four Presentations from Rigosertib Clinical Trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition
05/11/2018
Oral presentation on Saturday will feature efficacy and safety data from Expanded Phase 2 trial of rigosertib in combination with Azacitidine Three Poster presentations to feature pharmacokinetics, dose optimization, [...]
Milestone Scientific Receives Notice of Allowance for New U.S. Patent
05/11/2018
LIVINGSTON, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Milestone Scientific Inc . (NYSE: MLSS), a developer of computerized drug delivery instruments that provide painless and precise injections, today announced it has [...]
Terra Tech Corp. and Golden Leaf Holdings Ltd. Sign Non-Binding Letter of Intent to Merge
05/11/2018
Combined Company to Control 41 Permits Across Cultivation, Manufacturing, Distribution and Retail Spanning Oregon, California and Nevada, in Addition to 21 Pending Permit Applications in Multiple Jurisdictions [...]
ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions
05/11/2018
Approximately 25% risk reduction for recurrence of AF seen in favor of Gencaro over active comparator as measured by AFB WESTMINSTER, Colo., Nov. 05, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a [...]
CLS Holdings USA Loans $5 Million to In Good Health, Continuing on its Path to Enter the Rapidly Expanding Massachusetts Market
05/11/2018
LAS VEGAS, Nov. 05, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada [...]
Letter to Shareholders from Curt Fairbrother CEO, MedTainer Inc.
05/11/2018
CORONA, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dear Shareholders: Tomorrow’s elections signify another milestone in the final run-up to the United States government changing, for all time, the current Schedule 1 [...]
NeoChord Announces $25 Million Series D Financing to Accelerate Development of Two Transcatheter Chordal Repair Programs
05/11/2018
ST. LOUIS PARK, Minn., Nov. 05, 2018 (GLOBE NEWSWIRE) -- NeoChord, Inc. , a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve [...]
International Stem Cell Corporation Announces Positive Top-Line Preliminary Results from Parkinson’s Disease Clinical Trial
05/11/2018
CARLSBAD, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) ( www.internationalstemcell.com ) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company [...]
High Hampton Signs LOI to Acquire California Extracts Manufacturer -- CFN Media
05/11/2018
SEATTLE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]
Rothman Orthopaedic Institute implements Allscripts® Practice Management (PM) to strengthen financial coordination and operational efficiency
05/11/2018
Allscripts PM solution goes live at one of the world’s leading orthopedic institutes CHICAGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ:MDRX) partnered with Rothman Orthopaedic Institute to deliver Allscripts [...]
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
05/11/2018
PLYMOUTH MEETING, Pa., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that the Company will participate in the following upcoming investment conferences: Stifel 2018 [...]
MyoKardia to Present Clinical Evidence of Mavacamten’s Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions
05/11/2018
Diastolic Relaxation Typically Impaired in HCM Patients; Data Indicate Mavacamten May Improve Ability of the Left Ventricle to Relax and Fill Additional Clinical Evidence of Mavacamten’s Effect on Diastolic Function [...]
Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting
05/11/2018
NORCROSS, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based on results obtained [...]
Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial
05/11/2018
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments [...]
AIT Therapeutics to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
05/11/2018
GARDEN CITY, N.Y. and REHOVOT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO [...]
Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences
05/11/2018
HOPKINTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, [...]
Samumed Announces Multiple Presentations at 6th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD)
05/11/2018
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present clinical and preclinical data on the company’s small molecule Wnt pathway inhibitor, SM04690, in four poster presentations [...]
Rexahn Reports Third Quarter 2018 Financial Results
05/11/2018
ROCKVILLE, Md., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, [...]
Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
05/11/2018
Top-line Results Expected in First Quarter of 2019 SANTA MONICA, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological [...]

Pages